Last update June 23, 2022

N05AA02

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

Levomepromazine is a typical, first generation antipsychotic, phenothiazine, with pharmacological activity similar to that of both chlorpromazine and promethazine. Indicated in the treatment of schizophrenia and psychosis. It is also useful in the treatment of pain, nausea and vomiting of central origin and insomnia. Oral or intramuscular administration in 2 to 4 daily doses.

Since the last update we have not found any published data on its excretion in breast milk.

Given their powerful sedative effects, other drugs are preferable during breastfeeding.

Somnolence and adequate feeding of the infant should be monitored.

Because it can cause sedation and drowsiness, it is not recommended to share a bed (co-sleeping, bed-sharing) with the baby if this medication is being taken, due to increased risk of asphyxia or sudden infant deat


See below the information of this related product:

Alternatives

  • Chlorpromazine (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Olanzapine (Safe product and/or breastfeeding is the best option.)
  • Perphenazine (Safe product and/or breastfeeding is the best option.)
  • Trifluoperazine Hydrochloride (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Groups

N05AA02 belongs to these groups or families:

Tradenames

Main tradenames from several countries containing N05AA02 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 50 - 60 %
Molecular weight 329 daltons
VD 14 - 42 l/Kg
pKa 9.19 -
Tmax 1 - 3 hours
15 - 30 hours

References

  1. Sanofi. Levomepromazine (Nozinan). Drug Summary. 2020 Full text (in our servers)
  2. Sanofi. Levomepromazina (Sinogan). Ficha técnica. 2019 Full text (in our servers)
  3. Bagli M, Höflich G, Rao ML, Langer M, Baumann P, Kolbinger M, Barlage U, Kasper S, Möller HJ. Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. Int J Clin Pharmacol Ther. 1995 Dec;33(12):646-52. Abstract
  4. Dahl SG. Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther. 1976 Apr;19(4):435-42. Abstract

Total visits

1,157

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM